On Oct. 15, the FDA’s Center for Drug Evaluation and Research (CDER) released the 2024 Accelerating Rare disease Cures (ARC) Program Annual Report. Since its launch in 2022, CDER’s ARC Program has become a key resource for the rare disease community and a driver of innovation in rare disease drug treatments.
Having built a strong foundation, the ARC Program is enthusiastic about the upcoming year as it continues to strengthen collaboration to accomplish even more progress in rare disease drug development.
